IL-4

IL-4 詳細

英語名Interleukin-4市販薬剤の数2
治験薬の数14ターゲットの別称MGC79402,B-cell stimulatory factor 1,Lymphocyte stimulatory factor 1,IL4,Interleukin 4,B_cell Stimulatory Factor 1,B Cell Growth Factor 1,Binetrakin,Pitrakinra,BSF-1,IL-4,Interleukin 4 Variant 2,BCGF-1,BCGF1,BSF1,Interleukin-4
研究&開発段階Approved
英語名Interleukin-4
ターゲットの別称MGC79402,B-cell stimulatory factor 1,Lymphocyte stimulatory factor 1,IL4,Interleukin 4,B_cell Stimulatory Factor 1,B Cell Growth Factor 1,Binetrakin,Pitrakinra,BSF-1,IL-4,Interleukin 4 Variant 2,BCGF-1,BCGF1,BSF1,Interleukin-4
市販薬剤の数2
治験薬の数14
研究&開発段階Approved

IL-4 製品リスト

  • 属性

    Protein (12)Kits (5)

  • 製品ライブラリ

    オンライン (15)研究中 (2)

  • Human (10)Mouse (3)Cynomolgus (3)Rabbit (1)

  • タグ

    Tag Free (3)His Tag & Avi Tag (3)His Tag (4)Fc Tag (2)- (5)

  • マーカー

    Unconjugated (9)Biotin-labeled (3)- (5)

IL-4バックグランド

Interleukin-4, is a cytokine that induces differentiation of naive helper T cells (Th0 cells to Th2 cells). In the presence of IL-4 and IL-13, cytokines that are produced in a Th-2 type response, particularly during allergy and parasitic infections, macrophages become differentially activated, And this cytokine is a ligand for interleukin 4 receptor. The interleukin 4 receptor also binds to IL13, which may contribute to many overlapping functions of this cytokine and IL13. STAT6, a signal transducer and activator of transcription, has been shown to play a central role in mediating the immune regulatory signal of this cytokine. Recently, researcher found that the cytokine IL-4 plays a key role in development of innate CD8+ T cells in the thymus of several gene-deficient mouse strains, including Itk, KLF2, CBP and Id3, without previous exposure to antigen.

IL-4分子の別称

IL4,BCGF1,BSF1

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
Dupilumab biosimilar (Jingxing Pharmaceutical)GS101; GS-101; GS-101 (Jingxing Pharmaceutical)Phase 3 ClinicalJiangsu Jingxing Pharmaceutical Technology Co LtdDermatitis, Atopic
詳細
Dupilumab biosimilar (Qilu Pharma)QL2108; QL-2108Phase 3 ClinicalQilu Pharmaceutical Co LtdAsthma; Dermatitis, Atopic; Prurigo
詳細
TilrekimigPF-07275315Phase 3 ClinicalPfizer IncAsthma; Dermatitis, Atopic; Pulmonary Disease, Chronic Obstructive
詳細
EblasakimabMK-6105; ASLAN-004; CSL-334Phase 2 ClinicalCsl Ltd, Merck Sharp & Dohme CorpDermatitis, Atopic; Hypersensitivity
詳細
Dectrekumab/VAK-694QBX-258Phase 2 ClinicalNovartis Pharma AgAsthma; Lymphedema
詳細
OCH-NCNP1OCH-NCNP1Phase 2 ClinicalKeio UniversityCrohn Disease; Multiple Sclerosis
詳細
OmpekimigPF-07264660Phase 2 ClinicalPfizer IncDermatitis, Atopic
詳細
AUP1602-CAUP-16; AUP1602-CPhase 2 ClinicalAurealisDiabetic Foot; Ulcer
詳細
Dupixent biosimilar (Chong Kun Dang Pharmaceutical)CKD-706Phase 1 ClinicalChong Kun Dang Pharmaceutical CorpDermatitis, Atopic
詳細
Dupilumab biosimilar (China Resources Biopharma)Phase 1 ClinicalChina Resources Biopharmaceutical Co LtdDermatitis, Atopic
詳細
Dupilumab biosimilar (Jiangsu Jingxing Pharma)Phase 1 ClinicalJiangsu Jingxing Pharmaceutical Technology Co LtdDermatitis, Atopic
詳細
Dupilumab biosimilar (Chengdu Kanghong)KH-816; KH816Phase 1 ClinicalChengdu Kanghong Biotechnologies Co LtdDermatitis, Atopic
詳細
Dupilumab biosimilar (Jushi Biopharma)Phase 1 ClinicalJushi Biopharmaceutical Co LtdDermatitis, Atopic
詳細
Dupilumab biosimilar (Bio-Thera Solutions)BAT2406; BAT-2406Phase 1 ClinicalBio-Thera Solutions LtdAsthma; Dermatitis, Atopic; Eosinophilic Esophagitis; Nasal Polyps; Prurigo Nodularis; Sinusitis
詳細

市販薬剤に関する情報

英語名研究コード研究開発ステージ会社オリジナル製品名最初に承認をした国最初の適応症最初に承認を受けた会社承認された日付適応症臨床試験
DupilumabREGN-668; SAR-231893ApprovedRegeneron Pharmaceuticals Inc, SanofiDupixent, 达必妥United StatesDermatitis, AtopicRegeneron Pharmaceuticals Inc2017-03-28Allergic Fungal Rhinosinusitis; Alopecia Areata; Angioedema; Aspergillosis, Allergic Bronchopulmonary; Asthma; Asthma, Aspirin-Induced; Chronic Urticaria; Colitis, Ulcerative; Conjunctivitis, Allergic; Coronavirus Disease 2019 (COVID-19); Dermatitis; Dermatitis, Atopic; Eczema; Eosinophilic Esophagitis; Eosinophilic gastroenteritis (EG); Genetic Diseases, Inborn; Hypereosinophilic Syndrome; Hypersensitivity; Hypersensitivity, Immediate; Keloid; Keratoconjunctivitis; Lichenoid Eruptions; Milk Hypersensitivity; Nasal Polyps; Nephrotic Syndrome; Neurodermatitis; Paranasal Sinus Diseases; Peanut Hypersensitivity; Pemphigoid, Bullous; Prostatic Neoplasms; Prurigo; Prurigo Nodularis; Pruritus; Pulmonary Disease, Chronic Obstructive; Respiration Disorders; Respiratory Sounds; Respiratory Tract Diseases; Rhinitis, Allergic; Scleroderma, Localized; Sinusitis; Skin Diseases; Skin Diseases, Eczematous; Sleep Apnea Syndromes; Urticaria
詳細
Berdazimer sodiumNVN-1000-SB-206-Novan; SB-206; MAP3-NONOate - SB-206; NVN1000-SB206; SB-019; NI-MC101; SB-207; SB-208; SB-204; SB-414ApprovedUniversity Of North Carolina At Chapel HillKINSOLUSTM, Zelsuvmi, ZELSUVMIUnited StatesMolluscum ContagiosumLnhc Inc2024-01-05Acne Vulgaris; Condylomata Acuminata; Dermatitis, Atopic; Molluscum Contagiosum; Psoriasis; Tinea Pedis
詳細

レビュー

  • M***e2023-06-15
    3評価
    We have used this kit to profile compounds. This kit is both reliable and easy to use, and it shipped quickly. The 96 test kit is also amenable to scaling to a 384 well format for additional screening capabilities. In our experience, the customer service at ACRO has always been prompt when inquiring about when items will be restocked and when they have shipped.
  • 詳細
  • 製品リスト
  • 市販薬剤に関する情報
  • レビュー
  • 治験薬に関する情報
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8